Kritik und Anregungen » Aged individuals are more prone

Serotonin-norepinephrine Reuptake Inhibitors Market Opportunities by 2024
by Metcarl · October 15 Zach Randolph Jersey , 2018


Serotonin-norepinephrine reuptake inhibitors (SNRIs) or dual – uptake inhibitors represent one of the newest but important classes of antidepressants, which are commonly prescribed for anxiety disorders and depression therapeutic treatment. SNRIs were first launched in the international markets in 1993, when the U.S. FDA approved first of its ressants, which are used as a second line treatment regimen for depression in addition to another antidepressants class called Selective Serotonin Reuptake Inhibitors (SSRIs). SNRIs work by blocking the re-absorption of two neurotransmitters in the brain Buddy Hield Jersey , namely Norepinephrine and serotonin, thus, increasing the level of these two neurotransmitters in the nerve cells. This property of SNRIs helps elevate the mood of an individual suffering from depression or any type of anxiety disorder. No severe side effects have been observed to be associated with SNRIs usage; however, a few common side effects, such as nausea, dry mouth DeMarcus Cousins Jersey , excessive sweating and dizziness are generally associated with this class of antidepressants.


Some of the major driving factors for the growth of this market include rising prevalence of depression and anxiety disorders globally, improved efficacy and reduced side effects of SNRIs available in the global market and rapidly increasing geriatric population. According to the WHO estimates, in 2012, more than 350 million people were found to be affected by depression worldwide. Similarly, the Anxiety and Depression Association of America (ADAA) estimated that, in 2012 Chris Webber Jersey , around 14.8 million people in the U.S. were suffering from depression only.


Aged individuals are more prone to several depression and anxiety disorders; hence, high geriatric population in most of the developed economies and increasing age of people in developing nations will also contribute towards the growth of this market in future. Improved efficacy along with the reduction in the side effects due to SNRIs will further contribute towards the growth of this market. Some of the major drugs from this class that are available in the global market include Desvenlafaxine (Pristiq), Duloxetine (Cymbalta), Levomilnacipran (Fetzima) and Venlafaxine (Effexor XR). However, the market for SNRIs may face challenges in future due to recent expirations of lot of SNRIs and a weak pipeline of drugs from this class of antidepressants, which will cause the introduction of a large number of generics in the global market.